Navigation Links
Palatin Technologies Announces Option for License to Bremelanotide in Europe
Date:11/13/2013

aceutical companies on commercialization of bremelanotide in the United States, and hope to be able to select a potential partner this year and proceed to negotiation of definitive agreements early next year."

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about the prospects of entering into one or more license agreements relating to bremelanotide, potential clinical trial results with bremelanotide, potential actions by regulatory agencies in the United States or Europe relating to bremelanotide, regulatory plans, development programs and the market potential of bremelanotide are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's act
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
2. Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
3. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
6. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
7. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
8. Patient Safety Technologies Reports Third Quarter 2013 Results
9. BioSpecifics Technologies Corp. Reports Third Quarter 2013 Financial Results
10. Certifications, Presentation of Study Results and Earnings Releases - Research Report on Agilent, Mindray, Bard, Tornier, and Life Technologies
11. Study Assesses New Tools, Technologies, and Approaches for Understanding and Communicating with Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... 14, 2014 The Brandeis Medical Center, led by Dr. ... premier and affordable laser tattoo removal experience with the advanced Astanza ... in providing high quality cosmetic services with cutting edge medical technology ... Southern California has seen a dramatic increase in ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... , FORT LAUDERDALE, Fla., Dec. 22 LifeSync ... purchased the Besson Patent Portfolio and other wireless vital ... the use of wireless, two-way, digital communication between patient-electrodes ... patient. The acquired patent portfolio includes additional wireless improvements ...
... , HULL, England and FT. SASKATCHEWAN, Canada, ... & Nephew plc (LSE: SN; NYSE: SNN ), ... substantially all of the assets of Nucryst Pharmaceuticals Corp. ("Nucryst") ... manufacturing assets from Nucryst,s Fort Saskatchewan, Canada operations and the ...
Cached Medicine Technology:Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp. 2Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp. 3
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... frozen stool from healthy, unrelated donors was safe ... diarrhea caused by Clostridium difficile , according ... Clinical Infectious Diseases and available online. Known ... effective whether given via a colonoscope or a ... make this promising treatment more readily available to ...
(Date:4/23/2014)... director at the National Institute of Arthritis and Musculoskeletal ... recipient of the Ross Prize in Molecular Medicine, conferred ... Medicine . The award will be given on June ... Manhattan, followed by scientific presentations by Dr. O,Shea and ... Institutes of Health. , The award, which includes a ...
(Date:4/23/2014)... have developed a way to detect and measure cancer ... particles with tails of synthetic DNA., A team led ... used gold nanoparticles to target and bind to fragments ... variants, which can indicate the presence and stage of ... in a cell can be determined by examining the ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... in the journal Annals of Neurology, says that radiation emitted ... is the first study to show that mobile phone affect ... ,Italian researchers found in the current study that ... brain closest to the phone when used for 45 minutes ...
... set of dietary guidelines. Apart from the dietary guidelines ... Dietary Guidelines, the revised Food Guide Pyramid and food ... ,All the guidelines though are given by different organizations ... by all are increased intake of fruit and vegetables, ...
... mosquito-transmitted viral fever//, has claimed two lives in Madhya ... officials said. ,The disease, which has been reported ... the state through villages in Betul district bordering Maharashtra, ... stooped posture to the victim as a result of ...
... symptom of Sj?gren’s (SHOW-grins) syndrome was found to be the ... periods. ,Typical signs and symptoms include dry, gritty ... causes difficulty swallowing, dental cavities and enlarged parotid glands. The ... and in front of your ears. Other signs and symptoms ...
... treatments has been accused of placing money before patients//, ... drug. <BR.,Patients suffering from cancer linked to asbestos will ... is pemetrexed disodium, after a study conducted ... ,The group analyzed the cost effectiveness of the ...
... is made easy but the new fat-busting laser treatment called SmartLipo. ... to be a quicker and less invasive form of liposuction//. It ... the double chins areas. About six cosmetic surgery clinics in ... treatment. ,But he Food and Drug Administration (FDA) has ...
Cached Medicine News:
Plastic micro-hematocrit capillary tubes from Globe Scientific Inc. are designed for use in 75 mm (3 inches) hematocrit centrifuges and come with many features....
Hemato-clad Hematocrit Tubes combine the precision of glass with the safety provided by a Mylar® overwrap. Now you can give your laboratory staff safety with no compromise in accuracy....
... Vivid 3 system is designed to address ... performance, and offer an even wider range ... the OR. From color flow imaging with ... new Vivid 3 offers a wealth of ...
... Volcano's new VH IVUS technology ... allow simplified interpretation of ultrasound images ... composition of each patient's atherosclerotic plaques. ... plaque component types: fibrous, fibro-fatty, dense ...
Medicine Products: